Search
Design Therapeutics Inc
DSGNAdd to Watchlist
15.640USD
+0.980+6.68%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
976.58MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+6.68%
5 Days
+13.50%
1 Month
+49.81%
6 Months
+71.87%
Year to Date
+66.74%
1 Year
+344.32%
Key Figures
14.740Open
15.670High
1.58MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.53%Turnover Ratio
14.660Prev. Close
14.220Low
17.39MTurnover
LossP/E Static
4.48P/B
0.00%Div Yield TTM
-29.80%ROA
17.25052wk High
1.97Volume Ratio
-49.59MNet Profit
62.44MShares
-1.1923EPS TTM
1.66Beta
-31.26%ROE
3.33052wk Low
9.89%Amplitude
--Gross Margin
976.58MMarket Cap
7.89Reward/Risk
5.12%Risk Rate
TradingKey Stock Score of Design Therapeutics Inc
Currency: USD Updated: 2026-07-01Key Insights
Design Therapeutics Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 111 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.00.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Design Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Design Therapeutics Inc Highlights
StrengthsRisks
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Undervalued
The company’s latest PE is -12.30, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 38.66M shares, increasing 1.75% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 2.61M shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
21.000
Target Price
+47.47%
Upside Space
Design Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Design Therapeutics Inc Info
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Ticker SymbolDSGN
CompanyDesign Therapeutics Inc
CEOShah (Pratik)
Websitehttps://www.designtx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
FAQs
What is the current price of Design Therapeutics Inc (DSGN)?
The current price of Design Therapeutics Inc (DSGN) is 14.66.
What is the symbol of Design Therapeutics Inc?
The ticker symbol of Design Therapeutics Inc is DSGN.
What is the 52-week high of Design Therapeutics Inc?
The 52-week high of Design Therapeutics Inc is 17.25.
What is the 52-week low of Design Therapeutics Inc?
The 52-week low of Design Therapeutics Inc is 3.33.
What is the market capitalization of Design Therapeutics Inc?
The market capitalization of Design Therapeutics Inc is 915.62M.
Is Design Therapeutics Inc (DSGN) currently rated as Buy, Hold, or Sell?
According to analysts, Design Therapeutics Inc (DSGN) has an overall rating of Buy, with a price target of 21.00.
What is the Earnings Per Share (EPS TTM) of Design Therapeutics Inc (DSGN)?
The Earnings Per Share (EPS TTM) of Design Therapeutics Inc (DSGN) is -1.22.